Prometheus Biosciences to Present at Upcoming Investor Conferences
November 02 2021 - 8:00AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, starting first with inflammatory bowel
disease (IBD), today announced that management will be conducting
presentations and fireside chats at the following investor
conferences in November and December.
-
Credit Suisse 30th Annual Healthcare Conference –
Fireside Chat Tuesday, November 9th at 4:20 PM EST
-
Guggenheim 3rd Annual Neuro/Immunology Conference
– Fireside Chat Monday, November 15th at 10:20 AM EST
-
Jefferies London Healthcare Conference –
Presentation Tuesday, November 16th at 1:40 PM EST
-
Stifel 2021 Healthcare Conference – Presentation
Tuesday, November 16th at 4:00 PM EST
-
Piper Sandler 33rd Annual Healthcare Conference –
Fireside Chat available on Monday, November 22nd at 10:00 AM
EST
-
Evercore ISI 4th Annual HealthCONx Conference –
Fireside Chat Thursday, December 2nd at 3:55 PM EST
A live and archived webcast of the fireside
chats and presentations will be available via the Events &
Webcasts section of the Prometheus Biosciences website. A replay of
the presentation will be available for 30 days following the
event.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated
diseases, starting first with inflammatory bowel disease (IBD). The
Company’s precision medicine platform, Prometheus360, combines
proprietary machine learning-based analytical approaches with one
of the world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets.
The Company’s lead candidate, PRA023, is an IgG1 humanized
monoclonal antibody (mAb) for the treatment of the two most common
forms of IBD, Ulcerative Colitis (UC) and Crohn’s Disease
(CD). The Company has initiated enrollment in a Phase 2 trial
in UC patients and a Phase 2a trial in CD patients, each utilizing
a genetic-based companion diagnostic designed to identify patients
more likely to respond to PRA023.
Prometheus Biosciences Contact:Noel KurdiVP
Investor Relations and Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media Contact:Jake RobisonCanaleComm, an
Ashfield Health Company(619)
849-5383jake.robison@canalecomm.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024